Good MorningThe equity market extended Wednesday's rebound on Thursday but might be headed nowhere fast. The S&P 500 advanced about 0.75% at the session's high but remains below critical resistance points, nearing overbought conditions without setting a new high. Because of elevated volatility and uncertainty, the market will likely top out soon and revert to the bottom of the recent range. Among the catalysts for the move is the upcoming FOMC meeting scheduled for Tuesday and Wednesday of next week.
Economic data and market expectations cause the volatility. On the one hand, inflation is cooling, but the outlook for the Fed to lower interest rates is also cooling. The critical detail is that the FOMC will lower interest rates this year, but likely at a slower pace than the market would like. The takeaway for investors is that FOMC is threading the needle regarding the soft landing, economic conditions remain healthy, and a broader stock market rally should follow. Featured: INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (Ad) 
|
Markets | | | U.S. stocks closed out their best week of the year with more gains on Friday and climbed to the cusp of their records.The S&P 500 rose 0.5% for a fifth straight gain and is just 0.7% below its all-time high set in July. Rallies for Microsoft, Broadcom and other big technology stocks helped it cl... Read the Full Story |
|
From Our Partners | | Washington is running out of money…And guess where they'll look next?
When governments go broke, they take from the people.
It's happened before, and it's happening again.
The Department of Justice just admitted that cash isn't legally YOUR property. | | Get your free guide now by clicking here >> |
|
Markets | | |
Summit Therapeutics Inc. (NASDAQ: SMMT) has seen a meteoric rise this month, surging over 106% after releasing positive clinical trial results for its experimental cancer therapy. Year-to-date, the stock is up a staggering 769%.
This sharp uptick in share price was driven by the results of ... Read the Full Story |
|
Markets | | | Maria Lettini already knew about the backlash going on in the United States against ESG investing, which takes the environment, social issues and corporate governance into account, when she took over as chief executive of US SIF last year Read the Full Story |
|
From Our Partners | | Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. | | Click here to see the details on what could be the biggest tech story of this decade. |
|
Stocks | | | U.S. stocks pulled closer to their records on Thursday following a couple reports on the economy that came in close to expectations.The S&P 500 rose 0.7% and climbed back within 1.3% of its record set in July following a shaky summer. It remains on track for a fourth winning week in the last fi... Read the Full Story |
|
Stocks | | |
The past few years have been turbulent for Chinese companies listed on U.S. exchanges. Their stock prices have floundered despite major U.S. indexes reaching new heights. This disconnect is primarily driven by escalating political tensions between the U.S. and China and a lack of clarity regarding... Read the Full Story |
|
From Our Partners | | New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | | See Altucher’s Trump crypto prediction here |
|
Markets | | |
Exchange-traded funds (ETFs) are typically considered to be suitable investments for retail investors who have a hands-off approach. The built-in portfolio diversity inherent to many of these funds and the ability to hand over management of a fund's basket of securities to a team of professional m... Read the Full Story |
|
Markets | | | A report by the American Chamber of Commerce in Shanghai has found that U.S. companies in China are seeing record-low profits, with business confidence at an all-time low amid U.S.-China tensions and a slowing Chinese economy Read the Full Story |
|
Markets | | | Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even.The company also forecast a 2025 revenue range that fell below Wall Street expectations.Moderna said it planned an approximately... Read the Full Story |
|
Markets | | |
Tech device nerds are buzzing. Apple (NASDAQ: AAPL) just unveiled its new, AI-capable iPhone 16s. However, the excitement isn’t just around the devices themselves; investors are also talking. Wedbush raised their price target immediately after the official event displaying the new devices, w... Read the Full Story |
|
Markets | | |
Treasury bonds are the cornerstone of many investment portfolios, offering investors a safe and reliable way to invest in the U.S. government. These long-term debt securities are backed by the full faith and credit of the U.S. government, making them one of the most secure investment options avail... Read the Full Story |
|
Friday's Early Bird Stock Of The Day AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. | | View Today's Stock Pick |
|
